Skip to content

Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System

Telephone Linked Care for Cancer Symptom Management

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01979146
Enrollment
250
Registered
2013-11-08
Start date
2001-04-30
Completion date
2004-03-31
Last updated
2017-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Cancer

Brief summary

The purpose of this study was to test the efficacy of a computer-based automated symptom monitoring telephone system used by patients who received chemotherapy for their cancer to communicate unrelieved symptoms they experienced to their oncology providers.

Detailed description

The purpose of this study was to test the efficacy of a computer-based automated symptom monitoring telephone system used by patients who received chemotherapy for their cancer to communicate unrelieved symptoms they experienced to their oncology providers. The symptoms monitored in the project were nausea/vomiting, pain, sore mouth, diarrhea, constipation, depressed mood, anxiety, trouble sleeping, and fatigue. The study randomly assigned participants into either the intervention group or the group that received usual care from their oncology providers without alert notifications. All participants called the automated system daily to report their symptom presence, severity, and distress. When participants in the intervention group rated symptoms at moderate (4-7) to severe (8-10) levels an e-mail alert report of their symptom information was sent to the participant's medical oncologist and oncology nurse. The usual care group also reported symptoms daily to the automated system but their information was not sent to the providers. Participants in the usual care group were told daily to call their oncology provider if they had concerns about their symptoms. The two study groups were compared over chemotherapy cycles 2 and 3 on symptom presence, severity, and distress. Functional status, patient reported degree of symptom interference with normal activities, and work attendance if they had indicated that they worked during their treatment were also recorded. In addition, the groups were compared for the number and purpose of unscheduled patient-provider contacts, visits to the emergency department or urgent care facility, and unscheduled hospitalizations.

Interventions

OTHERProvider Unrelieved Symptom Alert

The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult (18 or older) * Histological Diagnosis of Cancer * Life Expectancy of at least 6 months * Cognitively able to participate (verified by provider team) * Initiated a course of new Chemotherapy that is planned for a minimum of 3 cycles * Had Poorly controlled symptoms during the first cycle of chemotherapy * Care under the direction of one of the designated provider teams * English or Spanish speaking * Has access to a telephone on a daily basis * Able to use the telephone unassisted

Exclusion criteria

* Receiving concurrent radiation therapy because they would be in daily contact with oncology care providers. * Patients seeing the provider team for recommendation of chemotherapy regimen but other providers then administer treatment at different site * Patients receiving a treatment regimen with only biotherapy agents or agents not associated with the symptoms monitored

Design outcomes

Primary

MeasureTime frameDescription
Patient reported symptom levels on a 0-10 scalepatients report symptoms daily for the duration of the study, an expected average of 6 weeksDuring daily automated calls, patients provided information about common chemotherapy symptoms.

Secondary

MeasureTime frameDescription
Medical Encounters Telephone Interviewparticipants will be followed for an expected average of 6 weeksWhen a patient reports during their daily phone call with the automated symptom monitoring system that they had been in contact with a health care provider, the research staff would conduct a short telephone interview to collect data about the nature of the medical encounter including whether the medical encounter was related to the symptoms being monitored by the system.
Functional Statusmonthly for the duration of the study, participants will be followed for an expected average of 6 weeksThe SF-12 was administered monthly to measure functional status.
Work Attendancereported daily, participants will be followed for an expected average of 6 weeksPatients who indicated at study enrollment that they planned to work during treatment answered a yes/no question during the automated symptom monitoring system call to report whether or not they worked the previous day.

Other

MeasureTime frameDescription
Patient End of Study Telephone Interviewadministered at the end of participation in the study, participants will be followed for an expected average of 6 weeksAn End of Study Telephone Interview was conducted at the end of a patient's participation in the project to obtain data on patient satisfaction with the symptom monitoring system and to obtain suggestions for improvement of the system.
Provider End of Study InterviewOnce, at the end of participation which is an expected average of 24 monthsAt the end of the study, participating providers were interviewed regarding the acceptability and use of the symptom alert reports and their suggestions for improvement.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026